OverviewSuggest Edit

RenovaCare, Inc. is a biotechnology company focused on developing first-of-their-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. The Company's initial products under development target the body’s largest organ, the skin. The Company's flagship technology, the CellMist System, uses our patented SkinGun to spray a liquid suspension of a patient’s stem cells – the CellMist Solution – onto wounds. RenovaCare, Inc. is also developing medical-grade liquid spray devices for wound care and irrigation fluids.

TypePublic
HQNew York, US
Websiterenovacareinc.com

Latest Updates

Employees (est.) (Dec 2018)1

Key People/Management at RenovaCare

Thomas Bold

Thomas Bold

President & CEO, CFO
Kenneth Kirkland

Kenneth Kirkland

Director
Roger Esteban-Vives

Roger Esteban-Vives

Director of Cell Sciences
Harmel S. Rayat

Harmel S. Rayat

Chairman, Board of Directors
Rodney Sparks

Rodney Sparks

Advisor
Richard Simman

Richard Simman

Advisor
Show more

RenovaCare Office Locations

RenovaCare has an office in New York
New York, US (HQ)
430 Park Ave #702
Show all (1)

RenovaCare Financials and Metrics

RenovaCare Revenue

USD

Net income (Q1, 2019)

(519.3k)

EBIT (Q1, 2019)

(604.0k)

Market capitalization (8-Oct-2018)

72.1m

Cash (31-Mar-2019)

14.9m
RenovaCare's current market capitalization is $72.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

628.5k1.2m1.0m1.6m2.1m1.6m

R&D expense

975.7k281.2k309.5k574.1k369.0k

Operating expense total

628.5k2.1m1.3m1.9m2.7m2.0m

EBIT

(1.9m)(2.7m)(2.0m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019

General and administrative expense

184.9k268.0k333.7k373.6k203.8k165.7k216.4k669.1k453.5k223.8k303.0k861.4k434.9k449.6k341.2k409.5k

R&D expense

902.2k61.4k50.2k80.7k111.8k73.8k45.4k79.1k144.9k139.8k125.1k108.2k194.5k

Operating expense total

184.9k268.0k333.7k1.3m265.2k215.9k297.0k780.9k527.4k269.2k382.1k1.0m574.7k574.7k449.4k604.0k

Depreciation and amortization

237.0
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

1.5m683.1k397.6k418.0k2.9m15.4m

Current Assets

1.5m690.5k407.9k449.6k2.9m15.6m

Total Assets

1.8m853.4k560.7k603.3k3.1m15.7m

Accounts Payable

11.2k71.6k107.3k222.2k
Quarterly
USDQ3, 2013Q1, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019

Cash

236.1k1.3m370.6k1.2m905.9k837.9k276.1k687.7k528.1k442.9k1.1m2.4m2.0m14.9m

Current Assets

237.6k1.4m405.9k1.2m940.2k878.5k304.1k699.8k529.3k466.0k1.2m2.4m2.0m15.1m

Total Assets

910.2k1.6m558.7k1.3m1.1m1.0m457.0k852.6k683.0k619.6k1.3m2.5m2.1m15.2m

Accounts Payable

83.4k37.4k84.0k88.7k80.7k28.2k20.2k11.5k101.9k21.2k11.4k249.5k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(1.0m)(2.1m)(1.3m)(2.1m)(3.7m)(2.1m)

Depreciation and Amortization

53.0317.0317.0

Accounts Payable

(71.6k)107.3k114.8k

Cash From Operating Activities

(349.9k)(825.7k)(1.3m)(1.8m)(1.7m)(2.0m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019

Net Income

(279.8k)(268.0k)(601.7k)(1.9m)(265.2k)(481.1k)(778.2k)(780.9k)(1.3m)(1.6m)(571.8k)(1.8m)(2.7m)(649.1k)(1.1m)(519.3k)

Depreciation and Amortization

79.0158.0237.079.0159.079.0

Accounts Payable

7.9k77.9k(43.4k)20.2k11.5k101.9k(86.2k)(95.9k)27.3k

Cash From Operating Activities

(174.6k)(159.6k)(340.7k)(619.0k)(312.5k)(530.5k)(787.2k)(559.7k)(1.1m)(1.4m)(334.9k)(764.7k)(1.2m)(631.4k)(1.1m)
USDY, 2019

Financial Leverage

1 x
Show all financial metrics

RenovaCare Online and Social Media Presence

Embed Graph

RenovaCare News and Updates

Global Skin Burns Market Report 2019: Insights, Epidemiology and Market Forecasts 2017-2028 Featuring Pfizer, Avita Medical, Mallinckrodt & RenovaCare

DUBLIN, Feb. 26, 2019 /PRNewswire/ -- The "Skin Burns- Market Insights, Epidemiology and Market Forecast-2028" drug pipelines has been added to ResearchAndMarkets.com's offering. Skin Burns- Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding...

RenovaCare Blogs

RenovaCare Chairman Invests $15.5 Million to Fund SkinGun Regulatory Submissions and Clinical Trials

Scottsdale, AZ– November 29th, 2018 - RenovaCare, Inc., (Symbol: RCAR; www.renovacareinc.com) today announced an equity financing for $15.5 million from Kalen Capital Corporation,…

Mr. Steve Yan-Klassen Appointed as Chief Financial Officer

Scottsdale, AZ - October 26, 2018 - RenovaCare, Inc., (OTC: RCAR),developer of patented technologies* for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing,…

RenovaCare Frequently Asked Questions

  • Who are RenovaCare key executives?

    RenovaCare's key executives are Thomas Bold, Kenneth Kirkland and Roger Esteban-Vives.

  • How many employees does RenovaCare have?

    RenovaCare has 1 employees.

  • Who are RenovaCare competitors?

    Competitors of RenovaCare include PhaseBio Pharmaceuticals, Oncoinvent and Intra-Cellular Therapies.

  • Where is RenovaCare headquarters?

    RenovaCare headquarters is located at 430 Park Ave #702, New York.

  • Where are RenovaCare offices?

    RenovaCare has an office in New York.

  • How many offices does RenovaCare have?

    RenovaCare has 1 office.